Its pharmacological properties and selective functional antagonism of β1AR-mediated signaling make C11 a promising therapeutic candidate for the treatment of CPVT and other forms of cardiac disease associated with excessive β1AR activation. The gene discussed is ADRB1; the disease is catecholaminergic polymorphic ventricular tachycardia.